Literature DB >> 17668415

DNA profiling of primary serous ovarian and fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation-dependent probe amplification.

M E Nowee1, A M Snijders, D A P Rockx, R M de Wit, V M Kosma, K Hämäläinen, J P Schouten, R H M Verheijen, P J van Diest, D G Albertson, J C Dorsman.   

Abstract

Primary serous ovarian carcinoma (OVCA) and serous Fallopian tube carcinoma (FTC), both belonging to the BRCA-linked tumour spectrum, share many properties and are treated similarly. However, a detailed molecular comparison has been lacking. We hypothesized that comparative genomic studies of serous OVCAs and FTCs should point to gene regions critically involved in their tumorigenesis. Array comparative genomic hybridization (array CGH) analysis indicated that serous OVCAs and serous FTCs displayed common but also more distinctive patterns of recurrent changes. Targeted gene identification using a dedicated multiplex ligation-dependent probe amplification (MLPA) probe set directly identified EIF2C2 on 8q as a potentially important driver gene. Other previously unappreciated gained/amplified genes included PSMB4 on 1q, MTSS1 on 8q, TEAD4 and TSPAN9 on 12p, and BCAS4 on 20q. SPINT2 and ACTN4 on 19q were predominantly found in FTCs. Gains/amplifications of CCNE1 and MYC, often in conjunction with changes in genes of the AKT pathway, EVI1 and PTK2, seemed to be involved at earlier stages, whereas changes of ERBB2 were associated with advanced stages. The only BRCA1-mutated FTC shared common denominators with the sporadic tumours. In conclusion, the data suggest that serous OVCAs and FTCs, although related, exhibit differences in genomic profiles. In addition to known pathways, new genes/pathways are likely to be involved, with changes in an miRNA-associated gene, EIF2C2, as one important new feature. Dedicated MLPA sets constitute potentially important tools for differential diagnosis and may provide footholds for tailored therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17668415     DOI: 10.1002/path.2217

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  45 in total

1.  Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers.

Authors:  Chad J Creighton; Michael D Fountain; Zhifeng Yu; Ankur K Nagaraja; Huifeng Zhu; Mahjabeen Khan; Emuejevoke Olokpa; Azam Zariff; Preethi H Gunaratne; Martin M Matzuk; Matthew L Anderson
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.

Authors:  Wenjing Zhang; Yijun Gao; Peixue Li; Zhubing Shi; Tong Guo; Fei Li; Xiangkun Han; Yan Feng; Chao Zheng; Zuoyun Wang; Fuming Li; Haiquan Chen; Zhaocai Zhou; Lei Zhang; Hongbin Ji
Journal:  Cell Res       Date:  2014-01-24       Impact factor: 25.617

4.  LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer.

Authors:  Jennifer Permuth-Wey; Donghwa Kim; Ya-Yu Tsai; Hui-Yi Lin; Y Ann Chen; Jill Barnholtz-Sloan; Michael J Birrer; Gregory Bloom; Stephen J Chanock; Zhihua Chen; Daniel W Cramer; Julie M Cunningham; Getachew Dagne; Judith Ebbert-Syfrett; David Fenstermacher; Brooke L Fridley; Montserrat Garcia-Closas; Simon A Gayther; William Ge; Aleksandra Gentry-Maharaj; Jesus Gonzalez-Bosquet; Ellen L Goode; Edwin Iversen; Heather Jim; William Kong; John McLaughlin; Usha Menon; Alvaro N A Monteiro; Steven A Narod; Paul D P Pharoah; Catherine M Phelan; Xiaotao Qu; Susan J Ramus; Harvey Risch; Joellen M Schildkraut; Honglin Song; Heather Stockwell; Rebecca Sutphen; Kathryn L Terry; Jonathan Tyrer; Robert A Vierkant; Nicolas Wentzensen; Johnathan M Lancaster; Jin Q Cheng; Thomas A Sellers
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

5.  Prognostic significance of Tspan9 in gastric cancer.

Authors:  Tongtong Feng; Libin Sun; Weiwei Qi; Fei Pan; Jing Lv; Jing Guo; Shufen Zhao; Aiping Ding; Wensheng Qiu
Journal:  Mol Clin Oncol       Date:  2016-07-15

6.  A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.

Authors:  Ankur K Nagaraja; Chad J Creighton; Zhifeng Yu; Huifeng Zhu; Preethi H Gunaratne; Jeffrey G Reid; Emuejevoke Olokpa; Hiroaki Itamochi; Naoto T Ueno; Shannon M Hawkins; Matthew L Anderson; Martin M Matzuk
Journal:  Mol Endocrinol       Date:  2010-01-15

7.  Up-regulation of PSMB4 is associated with neuronal apoptosis after neuroinflammation induced by lipopolysaccharide.

Authors:  Jiansheng Shi; Xiaorong Liu; Changde Xu; Jianbin Ge; Jianbing Ren; Jun Wang; Xinjian Song; Shirong Dai; Weidong Tao; Hongjian Lu
Journal:  J Mol Histol       Date:  2015-08-18       Impact factor: 2.611

8.  MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Authors:  Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

9.  Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.

Authors:  Alison M Karst; Paul M Jones; Natalie Vena; Azra H Ligon; Joyce F Liu; Michelle S Hirsch; Dariush Etemadmoghadam; David D L Bowtell; Ronny Drapkin
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

10.  Methylation-specific multiplex ligation-dependent probe amplification in meningiomas.

Authors:  Christian Ewald; Thomas Hofmann; Susanne A Kuhn; Thomas Deufel; Christian Beetz; Rolf Kalff
Journal:  J Neurooncol       Date:  2008-09-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.